Suggestions
Journal Information
Vol. 30. Issue S1.
XXIV Brazilian Congress of Infectious Diseases 2025
(March 2026)
Cite
Cite
Share
Download PDF
More article options
Vol. 30. Issue S1.
XXIV Brazilian Congress of Infectious Diseases 2025
(March 2026)
658
Full text access

EVALUATION OF COVID-19–ASSOCIATED MORTALITY BASED ON GENOMIC, CLINICAL, AND EPIDEMIOLOGICAL DATA: A RETROSPECTIVE COHORT STUDY IN A TERTIARY PUBLIC HOSPITAL.

Visits
452
Yasmim Colins Silva de Oliveiraa,
Corresponding author
yasmimcolins@usp.br

Corresponding author.
, Michel Morais Marques Sawana, Guilherme Silveira Castroa, Paula Capretz Agya, Patricia Marteleto Scanaveza, Aparecida Yulie Yamamotoa, Mateus Rennó de Camposa, Rosane Aparecida Monteiroa, Gilberto Gambero Gaspara, Benedito Antônio Lopes da Fonsecaa, Leandro Machado Collia, Felipe Santos de Carvalhob, Fernando Bellissimo-Rodriguesa
a Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
b Universidade Federal de São Carlos (UFSCar), São Carlos, SP, Brazil
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 30. Issue S1

XXIV Brazilian Congress of Infectious Diseases 2025

More info
Introduction/Objectives

The public health emergency caused by the SARS-CoV-2 pandemic resulted in a high number of severe cases and deaths. This study aimed to evaluate clinical, epidemiological, and genomic aspects related to COVID-19, in order to identify factors that may predict the risk of disease worsening and COVID-19–related death.

Methods

This retrospective cohort study evaluated nasopharyngeal and/or oropharyngeal secretion samples from patients with positive real-time RT-PCR results for SARS-CoV-2, treated at a tertiary public university hospital between April 4, 2020, and January 31, 2022. Samples with Ct values ≤30 were selected and fully sequenced. A total of 2,395 distinct samples corresponding to 2,379 patients were obtained. Complementary information—such as personal and epidemiological history, clinical manifestations, length of hospital stay, ICU requirement, and disease severity—was collected from electronic medical records and Epidemiological Surveillance data to analyze the final outcome (recovery or death).

Results

Among the 2,395 patients, 1,943 (81.1%) presented mild to moderate symptoms, 206 (8.6%) severe disease, and 210 (8.8%) critical disease. A total of 656 patients (27.4%) required hospitalization, and 282 (11.7%) required ICU admission, with a mean ICU stay of 14.5 days. Of the patients, 1,469 (61.3%) were female and 926 (38.7%) male. The mean age was 42.2 years among survivors and 63.3 years among those who died. The Original strain accounted for 923 infections (38.3%), followed by the Gamma genotype with 773 cases (30%), which was the most strongly associated with death (12.8%). Multivariate logistic regression analysis identified age (OR 1045.566; 95% CI 1032.739–1058.552), neoplasms (OR 2.55; 95% CI 1.408–4.638), and clinical presentation (OR 3169.781; 95% CI 1723.513–5829.669) as relevant variables associated with death. Vaccination (OR 0.704; 95% CI 0.524–0.948) and being a healthcare worker (OR 0.088; 95% CI 0.025–0.302) behaved as protective factors for the primary outcome.

Conclusion

The data show that advanced age, underlying neoplasms, and more severe COVID-19 cases were more strongly associated with death. Conversely, being a hospital employee and vaccination were protective factors against the worst outcome. These findings are useful for COVID-19 case management.

Keywords:
COVID-19
Mortality
SARS-CoV-2
Epidemiology
Genomics
Full text is only available in PDF
Download PDF
The Brazilian Journal of Infectious Diseases
Article options
Tools